BRIEF-Celgene says patients who recieved prior HMA therapies and CC-486 had a 38 pct overall response rate
December 05, 2016 at 20:28 PM EST
* patients with MDS, CMML or AML who were relapsed or refractory to prior HMA therapies and who received CC-486 had a 38% overall response rate
